We are a precision oncology company pioneering the development of cancer therapies guided by functional genomics.

We develop treatments for patients with genetically defined cancers, whose current treatment options are limited.
A UNIQUE APPROACH

To address the unmet needs of a diverse patient population, we’ve developed unique AI-supported drug discovery methods that accurately identify oncogenic yet untargeted mutations, then match them to potential drug candidates in a tumor-agnostic fashion.

THE FORESIGHT PLATFORM

Our approach is supported by our proprietary technology platform, Foresight. Foresight recapitulates hundreds of naturally occurring mutations in-vitro and monitors their effect on signaling pathway activity, in order to predict their oncogenicity and their response to experimental compounds.

Our Lead Program

Our lead program focuses on FORE-8394, an investigational drug identified by our platform for its inhibitory effect across a wide range of unique BRAF mutations.

FORE-8394 Clinical Trial
Following strong pre-clinical results, an active phase 1/2 study is currently underway to assess the safety, pharmacokinetics and pharmacodynamics of drug FORE-8394 in patients with advanced, unresectable solid tumors. For information about the study or to check suitability for enrolling as a new patient, please contact us via the attached form or at trials@fore.bio.
OUR INVESTORS

Fore is backed by top investors with deep
knowledge and experience in company formation.

For more information about the ongoing FORE-8394 clinical trial: